
Metosartan CH 6.25mg/50mg/40mg Tablet ER
Marketer
Sun Pharmaceutical Industries Ltd
Salt Composition
Chlorthalidone (6.25mg) + Metoprolol Succinate (50mg) + Telmisartan (40mg)
Overview Metosartan CH 6.25mg/50mg/40mg Tablet ER
This extended-release combination medication, Metosartan CH (6.25mg/50mg/40mg), treats hypertension by promoting vascular relaxation and improving cardiac output. It also facilitates diuresis, eliminating excess fluid and electrolytes. Metosartan CH can be administered with or without food, but consistent timing maximizes effectiveness. Due to its diuretic action, daytime ingestion, at least four hours before sleep, minimizes nocturnal urination. Dosage and frequency are determined by your physician based on your individual needs and should be followed precisely. Treatment should continue as prescribed. Common side effects include nausea, altered taste perception, diarrhea, and gastrointestinal distress. Regular monitoring of renal function and electrolyte levels is crucial. Optimal results are achieved when combined with lifestyle modifications such as balanced nutrition, regular physical activity, and smoking cessation. Increased fluid intake is recommended to counteract potential dryness of the mouth or excessive thirst. Prior to initiating therapy, inform your physician of any pregnancy, circulatory disorders, liver or kidney disease, and all other concurrent medications, as interactions may reduce efficacy or alter the drug's effects.
Primary Ingredients of Metosartan CH 6.25mg/50mg/40mg Tablet ER
No information provided. Please provide the text you wish to be rephrased.
Uses of Metosartan CH 6.25mg/50mg/40mg Tablet ER
Elevated arterial blood pressure
Major Benefits of Metosartan CH 6.25mg/50mg/40mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Metosartan CH 6.25mg/50mg/40mg Extended-Release tablet whole; avoid chewing, crushing, or breaking it. While this medicine can be taken with or without food, consistent daily timing is recommended.
Common Side effects of Metosartan CH 6.25mg/50mg/40mg Tablet ER:
- Nausea
- Taste change
- Diarrhea
- Upset stomach
- Headache
- Dizziness
- Weakness
- Cold extremities
- Numbness of extremity
- Increased uric acid level in blood
- Increased blood lipid level
- Decreased magnesium level in blood
- Slow heart rate
- Decreased sodium level in blood
- Decreased blood pressure
How to use Metosartan CH 6.25mg/50mg/40mg Tablet ER:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment period. Ingest the Metosartan CH 6.25mg/50mg/40mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. While it can be taken with or without food, consistent daily timing is recommended.
How Metosartan CH 6.25mg/50mg/40mg Tablet ER works:
A single tablet, Metosartan CH ER (6.25mg/50mg/40mg chlorthalidone/metoprolol succinate/telmisartan), combines three blood pressure-reducing agents for effective hypertension management.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use with Metosartan CH 6.25mg/50mg/40mg Extended-Release tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Extended-release Metosartan CH tablets (6.25mg/50mg/40mg) pose a confirmed risk to fetal development and should not be taken during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingSAFE IF PRESCRIBED
Extended-release Metosartan CH tablets (6.25mg/50mg/40mg) are likely safe for breastfeeding mothers. Available human data indicates minimal risk to the infant.
DrivingUNSAFE
Extended-release Metosartan CH tablets (6.25mg/50mg/40mg) can cause drowsiness, blurred vision, and dizziness. Refrain from driving if these effects are experienced.
KidneyCAUTION
Patients with severe kidney impairment should use Metosartan CH 6.25mg/50mg/40mg Extended-Release tablets cautiously, potentially requiring dosage modification. Physician consultation is advised; use in such patients is generally discouraged.
LiverCAUTION
Patients with liver impairment should use Metosartan CH 6.25mg/50mg/40mg Extended-Release tablets cautiously, potentially requiring dosage modification. Severe hepatic dysfunction contraindicates the use of Metosartan CH 6.25mg/50mg/40mg Extended-Release tablets; physician consultation is advised.
What if you forget to take Metosartan CH 6.25mg/50mg/40mg Tablet ER :
Should you forget to take your Metosartan CH 6.25mg/50mg/40mg Extended-Release tablet, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Metosartan CH 6.25mg/50mg/40mg Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Heart |
